"We present a pediatric case in which tissue damage developing after vincristine extravasation during treatment for Wilms tumor was managed with an amniotic membrane graft following clinical progression despite standard conservative measures" Ozen et al (2026).
Vincristine extravasation managed with amniotic membrane graft

Abstract:

Vincristine is a commonly used chemotherapeutic agent in pediatric oncology and, because of its vesicant properties, may cause severe tissue injury in cases of extravasation. We present a pediatric case in which tissue damage developing after vincristine extravasation during treatment for Wilms tumor was managed with an amniotic membrane graft following clinical progression despite standard conservative measures. A 2 year eight month old boy developed vincristine extravasation from a peripheral intravenous line on the dorsolateral aspect of the left foot during week 24 of carboplatin-vincristine chemotherapy for Stage II Wilms tumor. The progression of tissue injury despite initial conservative management suggested that amniotic membrane grafting may represent a useful alternative therapeutic option, especially in extravasation injuries involving functionally critical regions that do not respond adequately to conventional approaches.

Reference:

Ozen FB, Oz A, Aydin S. Case Report: Vincristine extravasation managed with amniotic membrane graft in a pediatric patient with Wilms tumor. Front Pediatr. 2026 Aug 19;14:1926830. doi: 10.3389/fped.2026.1926830. PMID: 42688325; PMCID: PMC13533990.